MARKET

RCUS

RCUS

Arcus Bioscience
NYSE
18.88
+0.67
+3.68%
After Hours: 18.50 -0.38 -2.01% 17:07 03/28 EDT
OPEN
18.30
PREV CLOSE
18.21
HIGH
19.11
LOW
18.18
VOLUME
744.39K
TURNOVER
0
52 WEEK HIGH
25.47
52 WEEK LOW
12.95
MARKET CAP
1.72B
P/E (TTM)
-4.5509
1D
5D
1M
3M
1Y
5Y
*Arcus Biosciences Grants Four New Employees Options to Purchase Total of 18,400 Shrs >RCUS
Dow Jones · 2d ago
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. Is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer. The company's Board of Directors granted four new employees options to purchase shares of the company's common stock.
Barchart · 2d ago
Arcus Biosciences Price Target Maintained With a $50.00/Share by Truist Securities
Dow Jones · 3d ago
Navigating 5 Analyst Ratings For Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The company has an average price target of $37.6 for the next 12 months. 5 analysts have provided ratings for Arcus B biosciences in the latest quarter. Arcus has been downgraded by 13.56% in the last 12 months from its average rating of 'buy' to 'neutral'
Benzinga · 3d ago
Truist Securities Reiterates Buy on Arcus Biosciences, Maintains $50 Price Target
Benzinga · 3d ago
Weekly Report: what happened at RCUS last week (0318-0322)?
Weekly Report · 4d ago
Chief Operating Officer Jennifer Jarrett Sold A Bunch Of Shares In Arcus Biosciences
Chief Operating Officer of Arcus Biosciences, Inc. Sold US$241k worth of stock at US$17.92 per share. The recent sale by Jennifer Jarrett amounts to 27% of the company's share price. In the last year, Arcus bioscience insiders have sold 26.01k shares at an average price of US$18.61. The company has a 2.4% stake in Arcus  . But the company is not the best stock to buy.
Simply Wall St · 03/22 10:04
We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth
Arcus Biosciences (NYSE:RCUS) has a negative free cash flow of US$330m. The company is burning through cash to fund its growth. Its annual cash burn equates to 21% of its market value. Arcus B biosciences has no debt and has 2.3 years of cash runway. We take a look at the company's revenue growth to see if shareholders should be worried about its cash burn.
Simply Wall St · 03/20 18:04
More
About RCUS
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Webull offers Arcus Biosciences Inc stock information, including NYSE: RCUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RCUS stock methods without spending real money on the virtual paper trading platform.